(Q34522758)

English

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

scientific article

Statements

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial (English)
0 references
0 references
0 references
0 references
Malcolm Ranson
Lisa A Hammond
David Ferry
Andrew Tullo
Vince Miller
Steve Averbuch
Charles Morris
Andrea Feyereislova
Helen Swaisland
Eric K Rowinsky
2240-2250

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit